This bill prohibits the Department of Health and Human Services (HHS), including the Food and Drug Administration (FDA), from treating pregnancy as an illness for specific regulatory purposes. This restriction applies to the approval of abortion drugs under section 505 of the Federal Food, Drug, and Cosmetic Act, as well as to the imposition or maintenance of risk evaluation and mitigation strategies (REMS) for such drugs. A key provision of the legislation is the nullification of any existing abortion drug approvals that relied, in whole or in part, on the classification of pregnancy as an illness. This nullification explicitly targets and includes the current approval of mifepristone , which would be revoked upon the bill's enactment. The overall intent is to alter the regulatory framework for abortion drugs by redefining how pregnancy is considered in their approval and oversight.